indibulin has been researched along with Benign Neoplasms in 4 studies
indibulin: Tubulin Modulator/Antineoplastic Agent; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " There was no significant difference in AUC of indibulin after multiple dosing (day 1-14) compared to single administration (day-4)." | 2.75 | Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. ( Beijnen, JH; Nol, A; Oostendorp, RL; Rosing, H; Schellens, JH; Schot, M; Schwartz, B; Vainchtein, LD; Voest, EE; Witteveen, PO, 2010) |
| "Indibulin is a synthetic small molecule which antitumor activity is based upon destabilization of microtubules." | 2.73 | Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors. ( Beijnen, JH; Daehling, A; Kuppens, IE; Schellens, JH; Schot, M; Schuessler, VM; Voest, EE; Witteveen, PO, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| James, DA | 1 |
| Koya, K | 1 |
| Li, H | 1 |
| Liang, G | 1 |
| Xia, Z | 1 |
| Ying, W | 1 |
| Wu, Y | 1 |
| Sun, L | 1 |
| Wan, Y | 1 |
| Li, Y | 1 |
| Yan, C | 1 |
| Yan, M | 1 |
| Tang, Z | 1 |
| Oostendorp, RL | 1 |
| Witteveen, PO | 2 |
| Schwartz, B | 1 |
| Vainchtein, LD | 1 |
| Schot, M | 2 |
| Nol, A | 1 |
| Rosing, H | 1 |
| Beijnen, JH | 2 |
| Voest, EE | 2 |
| Schellens, JH | 2 |
| Kuppens, IE | 1 |
| Schuessler, VM | 1 |
| Daehling, A | 1 |
1 review available for indibulin and Benign Neoplasms
| Article | Year |
|---|---|
Indole: A privileged scaffold for the design of anti-cancer agents.
Topics: Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Myeloid Cell | 2019 |
2 trials available for indibulin and Benign Neoplasms
| Article | Year |
|---|---|
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.
Topics: Acetamides; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under | 2010 |
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Topics: Acetamides; Administration, Oral; Adult; Aged; Antineoplastic Agents; Cross-Over Studies; Dose-Respo | 2007 |
1 other study available for indibulin and Benign Neoplasms
| Article | Year |
|---|---|
Indole- and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines.
Topics: Amides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette T | 2008 |